Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH. (Q44063021)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Marx M

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Langer T

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Hausdorf G

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Stöhr W

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Ludwig R

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Beck JD

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Pediatric Blood & Cancer

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

18-24

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Early anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Detection of anthracycline-induced cardiotoxicity.

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

[After-care of children and young adults surviving cancer. Initial recommendations by the late sequelae study group]

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Adriamycin cardiomyopathy--risk factors

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Dose-effect and structure-function relationships in doxorubicin cardiomyopathy

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac Catheterization

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Late cardiotoxicity after treatment for a malignant bone tumor

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Cardiac function in Wilms' tumor survivors

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Basic methods and the developing structure of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematolo

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Increased risk of cardiac dysfunction after anthracyclines in girls

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Cardiac disease following treatment of Hodgkin's disease in children and adolescents

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Cardiac dysfunction following spinal irradiation during childhood

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Late cardiotoxicity of anthracyclines in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Functional myocardial impairment in children treated with anthracyclines for cancer

1 reference

https://api.crossref.org/works/10.1002%2FMPO.10081

21 January 2018

Identifiers

10.1002/MPO.10081

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44063021&oldid=2106163527"